Abstract
Cytokines and chemokines are essential for establishing an appropriate immune response to severe acute respiratory syndrome coronavirus2 (SARSCoV2). Variations in the genes encoding cytokines and chemokines strongly influence the immune response to pathogenic challenges and disease outcomes. This study was carried out to determine the associations of polymorphisms in the TNFa, IL6, IL8, IL10, and CCL5 genes with COVID-19 severity. A total of 627 unvaccinated COVID-19 patients were classified according to WHO disease severity. We evaluated the levels of IFNa, IFNa TNFa, IL1R, IL6, IL7, IL10, CCL2, CCL3, CXCL8, CXCL10 and GCSF in the serum and were compared among COVID19 disease severity groups and stratified by polymorphism alleles. This study revealed a significant increase in IL2, IL6 and CCL2 levels in the dead group. However, the IL-10 levels were higher in the moderate group than in the mild group. Logistic regression analysis revealed that five polymorphisms were associated with an increased risk of severe COVID-19: the TNFa (rs1800610) A allele (OR=1.50; 95% CI: 1.01;2.24); the IL6 (rs1800796) C allele (OR=1.64; 95% CI: 1.05;2.57); the IL10 (rs1800871) T allele (OR=1.94; 95% CI: 1.24;3.04) and the IL-10 (rs1800872) A allele (OR=1.87; 95% CI: 1.21;2.89); and the CCL5 (rs3817656) G allele (OR= 1.64; 95% CI: 1.02;2.65)). The IL10 (rs1800871 and rs1800872) and IL6 (rs1800796 and rs18049563) gene polymorphisms were also associated with COVID-19 severity. Increases in IL6 and CCL2 serum levels in carriers of the risk allele rs1049953. In contrast, the IL10 levels were not associated with any of the SNPs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Consejo Nacional de Ciencia y Tecnologia; CONACYT 312513 SARS-COV 2.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethics committee of the Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra (INR-LGII:17/20).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos